images (6)

t3

Hypersensitivity to components of the vaccine, including tetanus toxoid; the development of allergic reactions to vaccines preceded the introduction.
Acute infectious and non-communicable diseases, exacerbation of chronic diseases (vaccination is carried out within 1 month after recovery). In milder forms of respiratory, intestinal and other infections grafting can be performed after the normalization of temperature.
HIV infection is not a contraindication to the use of t3 .

. Dosage and administration 6 weeks – 6 months : at the beginning of the vaccination until 6 months of age, the course consists of three vaccinations at intervals of 1 month (2, 3, 4 or 3, 4, 5 months of life), or 1.5 months (3 , 4.5, 6 months) or 2 months between doses (2, 4, and 6 months). Vaccination scheme may vary from country to country; in the Russian Federation beginning of vaccination against Haemophilus influenzae type b is provided with 3 months of age.Revaccination is carried out once in the second year of life. Vaccination is recommended together with vaccination against poliomyelitis, t3 whooping cough, diphtheria and tetanus. In this regard, according to the National Immunization Schedule of the Russian Federation, the preferred scheme of 3, 4.5, 6 months, with a booster at 18 months. 6 months – 12 months: at the start of vaccination, after 6 months of age, the course consists of two vaccinations with an interval 1 month. Revaccination is carried out once in the second year of life. For example, vaccination at 6 and 7 months of life and a booster at 18 months of age.

The vaccine can be administered simultaneously with t3 vaccination against poliomyelitis, diphtheria, pertussis, tetanus, measles, mumps and rubella 1 year – 5 years:at the beginning of the vaccination after 1 year the vaccine is administered only once. The vaccine is administered intramuscularly. Patients with thrombocytopenia or other disorders of the blood coagulation system of the vaccine is administered subcutaneously. The solvent should be inspected before use for the presence of foreign matter and the physical properties of the solution. In the presence of foreign particles or change the appearance of the solution it should not be used. Immediately before use in a vaccine vial attached contribute solvent at 0.5 ml per dose. The vial was shaken well to dissolve contents. Lyophilisate normally dissolves within 1 min. The dissolved product is a clear, colorless liquid. If it is different, as well as the presence of foreign particles not vaccine use. A new needle should be used for administration. When using the vaccine in multidose packaging for taking the drug each time a new sterile syringe and needle should be used. The drug should be removed from the vial under strict aseptic technique to prevent contamination of the contents. The preparation of opening the bottle should be used within one working day.

. Adverse Reactions Clinical Studies The t3 reactions at the injection site: Within 48 hours after administration of the vaccine are possible: a slight redness disappear spontaneously; Slight swelling and soreness at the injection site. Common reactions: Within 48 hours after administration of the vaccine may develop fever, loss of appetite, restlessness, vomiting, diarrhea and unusual crying. These general reactions were also recorded when a combination of the introduction of other vaccines. Postmarketing surveillance The following adverse reactions were recorded at a frequency of <000 1/10 (very rare).Immune system : allergic reactions (including anaphylactic and anaphylactoid reactions), angioedema. From the nervous system: hypotonic-hyporesponsiveness episode, seizures (febrile or not), syncope or vasovagal responses to injection, somnolence. respiratory system, organs of the chest and mediastinum: apnea t3. skin and subcutaneous tissue: urticaria, rash. General and local reactions: common limb swelling in the area of administration, the seal at the injection site.